2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1424

Impact of Glucocorticoid Therapy on the Efficacy of SC Abatacept or Adalimumab in RA Patients with Inadequate Response to MTX: A Post Hoc Analysis of Data from a Head-to-Head Trial
Abstract Number: 1425

Treatment Patterns in Patients with Rheumatoid Arthritis Newly Initiated on Biologic and Non-Biologic Therapy Enrolled in a North American Clinical Registry
Abstract Number: 1426

Higher Levels of Interleukin-6 As Well As Soluble Interleukin-6 Receptor Leads to Worse Clinical and Radiographic Prognosis in Rheumatoid Arthritis Patients Treated with Tocilizumab
Abstract Number: 1427

Monitoring of Absolute Lymphocyte Count in Patients with Rheumatoid Arthritis Treated with Tofacitinib
Abstract Number: 1428

Discovery and Characterization of JNJ-61178104, a Bispecific Antibody Against Human Tumor Necrosis Factor (TNF) Alpha and Interleukin (IL)-17A
Abstract Number: 1429

Incidence Rates of Adverse Events with Death As an Outcome during Abatacept Treatment in RA: Results from an Integrated Data Analysis from 16 Clinical Trials
Abstract Number: 1430

Switching from Synthetic to Biologic Dmards – Is There an Insufficient Use of Methotrexate?
Abstract Number: 1431

Serum Trough Levels of Adalimumab Inversely Correlate with Disease Activity in Patients with Inflammatory Arthritis
Abstract Number: 1432

The Prognostic Value of IgA Subtypes of Rheumatoid Factor and Anti-Citrullinated Protein Antibodies (ACPA) for Prediction of Therapeutic Responses to TNF Inhibitory Therapy in Patients with Rheumatoid Arthritis
Abstract Number: 1433

Tailoring Second-Line Biologic Therapy in Rheumatoid Arthritis: New Findings on the Usefulness of Antibody Status to Optimise Drug Selection
Abstract Number: 1434

COX-2 Inhibitor Contributes Cell Death in Rheumatoid Arthritis Fibroblast-like Synoviocytes Via PI3K/AKT/mTOR Signaling Pathway Triggered By Autophagy
Abstract Number: 1435

Consistent Inhibition of Joint Destruction By Denosumab in Important Subgroups of Japanese Patients with Rheumatoid Arthritis: Pooled Analysis of Phase 2 and 3 Studies
Abstract Number: 1436

Therapeutic Drug Monitoring on Rheumatoid Arthritis Patients with Reduced Doses of Intravenous Tocilizumab
Abstract Number: 1437

C-Reactive Protein Levels in Patients with or without Structural Progression: A Post-Hoc Analysis from a Phase 3 Tofacitinib Trial
Abstract Number: 1438

Is It Necessary to Weight By Weight the Dosage of MTX in RA Patients? Results from Obsevational Analysis of Baseline Data of a Phase III Trial

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].